Armata Pharmaceuticals (ARMP) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 10, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	AmpliPhi Biosciences Corp
Entity Central Index Key	921,114
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	APHB
Entity Common Stock, Shares Outstanding		5,883,503

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 11,737,000	$ 6,581,000
Accounts receivable	40,000	100,000
Prepaid expenses and other current assets	785,000	339,000
Total current assets	12,562,000	7,020,000
Property and equipment, net	1,162,000	1,220,000
In process research and development	12,446,000	12,446,000
Acquired patents, net	346,000	369,000
Goodwill	7,562,000	7,562,000
Total assets	34,078,000	28,617,000
Current liabilities
Accounts payable, accrued expenses and other	1,153,000	1,167,000
Deferred revenue	247,000	244,000
Accrued severance	491,000	457,000
Dividends payable	368,000
Total current liabilities	2,259,000	1,868,000
Series B preferred stock derivative liability	2,127,000	12,320,000
Warrant liability	10,000	5,826,000
Accrued severance		98,000
Deferred tax liability	3,078,000	3,078,000
Total liabilities	7,474,000	23,190,000
Series B redeemable convertible preferred stock
Preferred stock, $0.01 par value, 9,357,935 shares authorized at September 30, 2015 and December 31, 2014, 7,527,853 shares issued and outstanding at September 30, 2015 and 8,671,040 shares issued and outstanding at December 31, 2014 (liquidation preference of $13,068,000 and $14,042,000 at September 30, 2015 and December 31, 2014, respectively)	10,941,000	1,990,000
Stockholders' equity
Common stock, $0.01 par value, 670,000,000 shares authorized at September 30, 2015 and 445,000,000 shares authorized at December 31, 2014, 5,883,503 shares issued and outstanding at September 30, 2015 and 3,983,182 shares issued and outstanding December 31, 2014	59,000	40,000
Additional paid-in capital	375,895,000	365,403,000
Accumulated deficit	(360,291,000)	(362,006,000)
Total stockholders' equity (deficit)	15,663,000	3,437,000
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity	$ 34,078,000	$ 28,617,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Series B redeemable convertible preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Series B redeemable convertible preferred stock, shares authorized	9,357,935	9,357,935
Series B redeemable convertible preferred stock, shares issued	7,527,853	8,671,040
Series B redeemable convertible preferred stock, shares outstanding	7,527,853	8,671,040
Series B redeemable convertible preferred stock liquidation preference	$ 13,068,000	$ 14,042,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	670,000,000	445,000,000
Common stock, shares issued	5,883,503	3,983,182
Common stock, shares outstanding	5,883,503	3,983,182

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue	$ 143,000	$ 103,000	$ 347,000	$ 308,000
Operating expenses
Research and development	728,000	1,793,000	2,777,000	4,692,000
General and administrative	1,554,000	1,701,000	4,568,000	5,289,000
Severance expense	289,000	1,840,000	289,000	1,840,000
Total operating expenses	2,571,000	5,334,000	7,634,000	11,821,000
Loss from operations	(2,428,000)	(5,231,000)	(7,287,000)	(11,513,000)
Other income (expense)
Change in fair value of warrant liability	693,000	7,079,000	607,000	9,245,000
Change in fair value of Preferred B stock derivative liability	7,045,000	19,359,000	8,697,000	26,041,000
Other income	129,000
Other expense			(302,000)
Total other income	7,867,000	26,438,000	9,002,000	35,286,000
Net income	5,439,000	21,207,000	1,715,000	23,773,000
Accretion of Series B redeemable convertible preferred stock	(7,163,000)	(323,000)	(9,329,000)	(955,000)
Net (loss) income attributable to common stockholders	$ (1,724,000)	$ 20,884,000	$ (7,614,000)	$ 22,818,000
Per share information:
Net (loss) income per share of common stock - basic	$ (0.30)	$ 5.58	$ (1.45)	$ 6.19
Weighted average number of shares of common stock outstanding - basic	5,813,063	3,743,182	5,247,508	3,688,903
Net (loss) income per share of common stock - diluted	$ (0.30)	$ 3.30	$ (1.45)	$ 3.53
Weighted average number of shares of common stock outstanding - diluted	5,813,063	6,319,802	5,247,508	6,472,093

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Redeemable Convertible Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balances at Dec. 31, 2013	$ 707,000	$ 36,000	$ 362,454,000	$ (385,115,000)	$ (22,625,000)
Balances (in shares) at Dec. 31, 2013	8,859,978	3,650,711
Net income from operations				23,109,000	23,109,000
Accretion of dividends on Series B redeemable convertible preferred stock	$ 1,285,000		(1,285,000)		(1,285,000)
Conversion of Series B redeemable convertible preferred stock to common stock, value	$ (2,000)	$ 1,000	706,000		707,000
Conversion of Series B redeemable convertible preferred stock to common stock, shares	(188,938)	37,788
Warrants exercised		$ 1,000	1,594,000		1,595,000
Warrants exercised (in shares)		54,683
Stock-based compensation			775,000		775,000
Stock-based compensation - severance			1,161,000		1,161,000
Shares released from escrow		$ 2,000	(2,000)
Shares released from escrow (in shares)		240,000
Balances at Dec. 31, 2014	$ 1,990,000	$ 40,000	365,403,000	(362,006,000)	3,437,000
Balances (in shares) at Dec. 31, 2014	8,671,040	3,983,182
Net income from operations				1,715,000	1,715,000
Accretion of dividends on Series B redeemable convertible preferred stock	$ 992,000		(992,000)		(992,000)
Amount reclassified to Series B redeemable convertible stock to accrete to its redemption value	8,337,000		(8,337,000)		(8,337,000)
Conversion of Series B redeemable convertible preferred stock to common stock, value	$ (378,000)	$ 2,000	1,504,000		1,506,000
Conversion of Series B redeemable convertible preferred stock to common stock, shares	(1,143,187)	228,637
Common stock issued in March 2015 financing, net of fair value of warrants issued		$ 16,000	8,250,000		8,266,000
Common stock issued in March 2015 financing, net of fair value of warrants issued (in shares)		1,575,758
Warrants exercised		$ 1,000	1,072,000		1,073,000
Warrants exercised (in shares)		56,645
Warrants reclassified from liabilities to equity due to amendment of warrants			5,462,000		5,462,000
Warrants reclassified from liabilities to equity due to increase in authorized shares			3,280,000		$ 3,280,000
Exercise of common stock options (shares)		39,281			214,815
Stock-based compensation			249,000		$ 249,000
Stock-based compensation - severance			4,000		4,000
Balances at Sep. 30, 2015	$ 10,941,000	$ 59,000	$ 375,895,000	$ (360,291,000)	$ 15,663,000
Balances (in shares) at Sep. 30, 2015	7,527,853	5,883,503

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net income	$ 1,715,000	$ 23,773,000
Adjustments required to reconcile net income to net cash used in operating activities:
Change in fair value of warrant liability	(607,000)	(9,245,000)
Change in fair value of Series B preferred stock derivative liability	(8,697,000)	(26,041,000)
Gain on re-valuation of liquidated damages liability	(120,000)
Warrants issued to placement agents	213,000
Amortization of patents	23,000	23,000
Depreciation	217,000	59,000
Stock-based compensation	249,000	714,000
Stock-based compensation - severance	4,000	1,161,000
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable	60,000	(19,000)
Accounts payable, accrued expenses, deferred revenue and other	(11,000)	(305,000)
Accrued severance	(64,000)	659,000
Prepaid expenses and other current assets	(446,000)	(151,000)
Net cash used in operating activities	(7,464,000)	(9,372,000)
Investing activities:
Purchases of property and equipment	(160,000)	(1,197,000)
Net cash used in investing activities	(160,000)	(1,197,000)
Financing activities:
Proceeds from warrant exercises	396,000
Proceeds from issuance of private placement, net of offering costs	12,384,000
Net cash provided by financing activities	12,780,000
Net increase (decrease) in cash and cash equivalents	5,156,000	(10,569,000)
Cash and cash equivalents, beginning of period	6,581,000	20,355,000
Cash and cash equivalents, end of period	11,737,000	9,786,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	$ 9,329,000	$ 955,000
Fair value of warrant liability upon issuance	4,210,000

Organization and Description of

Organization and Description of the Business	9 Months Ended
	Sep. 30, 2015
Organization and Description of the Business [Abstract]
Organization and Description of the Business	1. Organization and Description of the Business AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company is dedicated to developing novel antibacterial therapies called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets. As a development stage company, it has incurred net losses since its inception , has negative operating cash flows, and had an accumulated deficit of $ 360.3 million and $ 362.0 million as of September 30, 2015 and December 31, 2014 , respectively. The Company completed a $ 13.0 million private placement of its common s tock in March 2015, which provided net proceeds of approximately $ 12.4 million after commissions to placement agents. In the opinion of management, the Company has resources sufficient to fund its planned operations through the third quarter of 2016. This estimate is based on the Company’s current product development plans , projected staffing expenses, working capital requirements, and capital expenditure plans.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 . Since the date of those financial statements, there have been no material changes to the Company’s significant accounting policies. The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited, Ampliphi d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10 ‑K, filed with the Securities and Exchange Commission (SEC). The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted account principles as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). In the opinion of management, the accompanying financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2015 and the results of its operations for the three and nine months ended September 30, 2015 and 2014 . Interim results are not necessarily indicative of results for the full year or any future period. Reverse Stock Split On August 3, 2015, the Company filed Articles of Amendment to Amended and Restated Articles of Incorporation with the Secretary of State of the State of Washington that effected a 1-for-50 (1: 50 ) reverse stock split of its common stock, par value $ 0.01 per share , effective August 7, 2015. On August 3, 2015, the Company increased its authorized common stock, from 445,000,000 to 670,000,000 shares. The par value of its common stock was unchanged at $0.01 per share, post-split. All warrant, stock option, and per share information in the consolidated financial statements gives retroactive effect to the 1-for-50 reverse stock split that was effected on August 7, 2015. Use of Estimates Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: the determination of the fair value of stock-based awards, the fair value of liability-classified preferred stock derivatives, the fair value of liability-classified warrants, the valuation of long-lived assets, including in-process research and development (IPR&D), patents and goodwill, accrued expenses and the recoverability of the Company's net deferred tax assets and related valuation allowance. Cash and Cash Equivalents Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions. Cash equivalents include short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost plus accrued interest, which approximates fair market value. Accounts Receivable Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on an assessment of the probable collection from specific customer accounts and other known factors. As of September 30, 2015 and December 31, 2014 , management determined no allowance for doubtful accounts was required. In-Process Research & Development and Goodwill In-process research & development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. We review the carrying value of IPR&D and goodwill for potential impairment on an annual basis and at any time that events or business conditions indicate that it may be impaired. As permitted under Accounting Standards Codification Topic 350 (ASC 350), through December 31, 2014 , we have elected to base our assessment of potential impairment on qualitative factors. Based on our assessment, IPR&D and goodwill were not impaired as of December 31, 2014 . Warrant and Preferred Shares Conversion Feature Liability The Company accounts for warrant and preferred share features with anti-dilution adjustment provisions under the applicable accounting guidance which requires the warrant and the preferred share feature to be recorded as a liability and adjusted to fair value at each reporting period. Foreign Currency Translations and Transactions The functional currency of our wholly-owned subsidiaries is the U.S. dollar. Other Comprehensive Income (Loss) The Company recorded no comprehensive income other than net income for the periods reported. Recent Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern , which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities - Derivative Instruments	9 Months Ended
	Sep. 30, 2015
Fair Value of Financial Assets and Liabilities - Derivative Instruments [Abstract]
Fair Value of Financial Assets and Liabilities - Derivative Instruments	3. Fair Value of Financial Assets and Liabilities — Derivative Instruments ASC Topic 820, Fair Value Measurement (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:  Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.  Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.  Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Items measured at fair value on a recurring basis include common stock warrants and embedded derivatives related to the Company’s redeemable convertible preferred stock. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The following fair value hierarchy table presents information about each major category of the Company's financial liabilities measured at fair value on a recurring basis: Quoted Prices in Active Markets Significant Other Significant for Identical Observable Inputs Unobservable Items (Level 1) (Level 2) Inputs (Level 3) Total September 30, 2015 Liabilities Series B preferred stock derivative liability $ - $ - $ $ Warrant liability - - Total liabilities $ - $ - $ $ December 31, 2014 Liabilities Series B preferred stock derivative liability $ - $ - $ $ Warrant liability - - Total liabilities $ - $ - $ $ There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy for the three and nine months ended September 30, 2015 and the year ended December 31, 2014 . The following table sets forth a summary of changes in the fair value of the Company's Series B redeemable convertible preferred stock derivative and warrant liability, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy, wherein fair value is estimated using significant unobservable inputs: Series B Preferred Warrant Stock Derivative Liability Liability Balance, December 31, 2014 $ $ Issuances - Exercises - Conversions to common stock - Warrants reclassified from liabilities to equity due to amendment of warrants - Warrants reclassified from liabilities to equity due to increase in authorized shares - Changes in estimated fair value Balance, September 30, 2015 $ $ The fair value of the warrants on the date of issuance and on each re-measurement date for warrants classified as liabilities is estimated using the Monte Carlo valuation model. For this liability, the Company develops its own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used at September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 Series (1) Series (1) June July December 2011 2011 2013 2013 2013 Volatility % % % % % Expected term (years) Risk-free interest rate % % % % % Dividend yield % % % % % Exercise price $ $ $ $ $ Common stock closing price $ $ $ $ $ (1) See Note 6 – Warrants below for further description of the respective series of warrants. The warrant liability is recorded on the accompanying consolidated balance s hee t s and is marked-to-market at each reporting period, with the change in fair value recorded as a component of change in fair value of warrant liability on the Company’s s tatement s of op erations. The fair value of the Series B preferred stock derivative liability on each measurement date is estimated using the Monte Carlo valuation model. For this liability, the Company develops its own assumptions that do not have observable inputs or available market d ata to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the expected term of the Series B preferred stock , risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the Series B preferred conversion liability is considered a Level 3 measurement. The following assumptions were used at September 30, 2015 and December 31, 2014 : September 30, December 31, 2015 2014 Volatility % % Expected term (years) Risk-free interest rate % % Common stock dividend yield % % Minimum non-diluting issuance price $ $ Common stock closing price $ $ The Series B preferred stock derivative liability is recorded on the accompanying consolidated bal ance s heet and is marked-to-market each reporting period, with the change in fair value recorded as a component of change in fair value of Series B preferred stock derivative liability on the Company’s s tatement s of o perations.

Net (Loss) Income per Common Sh

Net (Loss) Income per Common Share	9 Months Ended
	Sep. 30, 2015
Net (Loss) Income per Common Share [Abstract]
Net (Loss) Income per Common Share	4. Net (Loss) Income per Common Share The following table sets forth the computation of basic and diluted net (loss) income per share for the periods indicated: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Basic and diluted net (loss) income per common share calculation: Net income $ $ $ $ Accretion of Series B redeemable convertible preferred stock Net (loss) income attributable to common stockholders $ $ $ $ Weighted average common shares outstanding - basic Net income (loss) per share of common stock - basic $ $ $ $ Weighted average common shares outstanding - diluted Net income (loss) per share of common stock - diluted $ $ $ $ The following outstanding securities at September 30, 2015 and 2014 have been excluded from the computation of diluted weighted shares outstanding for the nine months ended September 30, 2015 and 2014 , as they would have been anti-dilutive: September 30, September 30, 2015 2014 Options Warrants - Series B redeemable convertible preferred stock as converted - Escrow - Total

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2015
Redeemable Convertible Preferred Stock [Abstract]
Redeemable Convertible Preferred Stock	5. Redeemable Convertible Preferred Stock On June 13, 2013, the Company’s Board of Directors approved a resolution designating 9,357,935 shares of Preferred Stock as Series B redeemable convertible preferred stock (Series B) with an initial stated value of $ 1.40 and par value of $ 0.01 . Each Series B share is convertible into 0.20 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock into which such Series B share may be converted . These Series B shares may be converted to common stock by the holder of the shares at any time. The Series B shares shall be automatically converted into common stock upon the closing of an underwritten initial public offering by the Company occurring after June 13, 2013 , with aggregate proceeds to the Company of at least $ 7.0 million and a price per share to the public of at least the Series B stated value of $1.40 per share upon the closing of which the shares of common stock of the Company are listed for trading on a major national stock exchange. Holders of the Series B shares are entitled to receive cumulative , cash dividends at the rate of 10 % of the Series B stated value. Such dividends accrue from day-to-day commencing on the original issue date, whether or not earned or declared by the Board of Directors, and are compounded annually . No dividends have been declared or paid through September 30, 2015 . At any time on or after June 26, 2018, the holders of at least two-thirds of the outstanding Series B shares may require the Company to redeem all of the outstanding Series B shares f or an amount equal to the original issue price per share plus any accrued and unpaid dividends. Holders of the Series B are entitled to a liquidation preference in an amount equal to the Series B stated value of $ 1.40 per share plus all accrued and unpaid dividends in the event of a liquidation, dissolution, or winding-up of the Company, or in the event the Company merges with or is acquired by another entity. In connection with the private placement of Series B, the Company recorded a liability for an embedded derivative that required bifurcation under the applicable accounting guidance. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with specified anti-dilution adjustments for certain financing transactions involving the issuance of securities at a price below a minimum non-diluting issuance price of $ 7.00 per share. The following table summarizes the conversions of Series B shares to common stock pursuant to Series B shareholder elections during the nine months ended September 30, 2015 : Amount Reclassified Series B Common from Liability Conversion Shares Stock into Stockholders' Date Converted Issued Equity (1) April 8, 2015 $ May 4, 2015 May 11, 2015 July 16, 2015 August 13, 2015 Totals $ (1) Not inclusive of liabilities for dividends payable upon conversion of these shares. The Company re-measured the fair value of the derivative feature and recorded a gain of $ 7,045,000 for the quarter ended September 30, 2015 to adjust the liability associated with the conversion feature to its estimated fair value of $ 2,127,000 as of September 30, 2015 . For the nine months ended September 30, 2015 , the Company recorded a gain of $ 8,697,000 related to the change in fair value of the derivative feature. At September 30, 2015 , the Company reclassified $ 8,337,000 from addition al paid-in capital to Series B r edeemable convertible preferred stock to adjust the redemption value of the S eries B to actual at that date, an increase of $ 6,845,000 from the $ 1,492,000 recorded at June 30, 2015, which was attributable to the reduction in the fair market value of the Series B stock derivative liability at September 30, 2015 as compared to June 30, 2015. At September 30, 2015 , the Company recorded dividends payable of $ 368,000 to former holders of preferred stock, which are classified as current liabilities on the Company’s Balance Sheet at that date.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Warrants [Abstract]
Warrants	6. Warrants In connection with the March 16, 2015 private placement of 1,575,758 shares of the Company’s common stock at a price per share of $ 8.25 , the Company issued warrants (Series March 2015) to purchase an aggregate of 393,939 shares of common stock at an exercise price of $ 10.75 per share to the purchasers of the common stock. In addition, the Company issued warrants to purchase an aggregate of 94,548 shares of common stock at an exercise price of $10.75 per share to the placement agents. These warrants expire in March 2020 and provided for a contingent cash payment of $ 2.5 million in liquidated damages to the holders of the warrant s in the event the Company failed to either (i) increase the number of sh ares of common s tock the Company is authorized to issue or (ii) effect a reverse split of the c ommon s tock, in either event sufficient to permit the exercise in full of the Warrants in accordance with their terms. Due to these provisions, the Company accounted for these warrants as liability instruments prior to the third quarter of 2015 . The Company measured the fair value of these warrants on March 16, 2015 and recorded an initial warrant liability of $ 4,210,000 , of which $ 3,396,000 represented the initial fair value of the warrants issued to investors and $ 814,000 as the initial fair value of the warrants issued to the placement agents. The Company recorded other expenses of $ 213,000 for the nine months ended September 30, 2015 representing a portion of the initial fair value of warrants issued to the placement agent s attributable to the initial fair value of the warrants issued . In connection with the December 2013 private placement of 1,440,140 shares of the Company’s common stock at a price per share of $ 12.50 , the Company issued warrants (Series December 2013) to purchase an aggregate of 86,408 shares of common stock at an exercise price of $ 12.50 per share to the placement agents. These warrants, which expire December 2018, contain specified anti-dilution adjustment provisions for certain financing transactions involving the issuance of securities below a specified price and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liability instruments. As a result of the March 16, 2015 private placement of common stock at a price of $8.25 per share, the anti-dilution adjustment provisions of these warrants resulted in an adjustment to their exercise price to $ 8.25 as of March 16, 2015. In connection with the private placement of Series B, which occurred through two closings on June 26, 2013 and July 15, 2013, the Company issued warrants (Series June 2013 and Series July 2013, respectively) to purchase an aggregate of 600,804 shares of common stock at an exercise price of $ 7.00 per share. These warrants, which expire in June 2018 and in July 2018 , respectively, contain anti-dilution adjustment provisions and contain net settlement provisions. Due to these provisions, the Company accounts for these warrants as liability instruments. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded initial warrant liabilities of $ 4,285,000 and $ 674,000 , respectively, as part of the private placement proceeds and expensed $ 759,000 for warrants issued to the placement agent. In January 2011, we completed the acquisition of Biocontrol Limited, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. On December 22, 2011, in connection with our acquisition of Biocontrol, the Company issued warrants (Series 2011) to purchase up to 27,103 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $ 23.00 per share. As the terms of these warrants require that they be settled in registered shares of common stock, the Company accounts for these warrants as liability instruments. The Company estimates the fair values of all warrants accounted for as liability instruments using a Monte Carlo valuation model. From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants (Series 2013 Convertible Notes Warrants) to purchase up to 140,608 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $ 7.00 per share. The Company classifies these warrants as equity instruments. On April 1, 2015, 52,120 warrants, issued on June 26, 2013, were exercised, resulting in the issuance of 52,120 shares of common stock and $ 630,000 being reclassified from the warrant liability account and into stockholders’ equity, based on the fair value of the warrants on the exercise date. On April 29, 2015, 4,524 warrants, issued on June 26, 2013, were exercised, resulting in the issuance of 4,524 shares of common stock and $ 46,000 was reclassified from the warrant liability account and into stockholders’ equity, based on the fair value of the warrants on the exercise date. On May 8, 2015, the Company, upon approval of more than two-thirds of the holders of the 2013 warrants issued on June 26, 2013, July 15, 2013 and December 23, 2013, amended thes e warrants to remove certain anti-dilution adjustment provisions . As a result of this amendment, all outstanding warrants from those issuance dates were reclassified as equity instruments resulting in the reclassification of $ 5,462,000 from the warrant liability to stockholders’ equity, reflecting the fair value of these warrants on the amendment date. On August 3, 2015, the shareholders of the Company approved a 1-for-50 reverse stock split of the Company’s common stock and increased the number of authorized shares of common stock to 670,000,000 . As a result, t he warrants issued in conjunction with the March 2015 private placement of common stock were reclassified from liability instruments to equity instruments. Accordingly, $ 3,281,000 was reclassified from warrant liability to stockholders’ equity, reflecting the fair value of these warrants on the effective date of the reverse split, and the accrued fair value of liquidated damages in the amount of $ 120,000 were also reclassified to stockholders’ equity. The Company re-measured the fair value of the warrant liability and recorded a gain of $ 693,000 for the quarter ended September 30, 2015 , reflecting a decrease in the liability associated with the warrants at their estimated fair value, which totaled $ 10,000 as o f September 30, 2015 . For the nine months ended September 30, 2015 the Company recorded a gain of $ 607,000 related to the change in fair value of the warrants for that period. All exercise prices and share amounts of warrants are after giving consideration to the 1-for-50 reverse split of the Company’s common stock which was effective August 7, 2015. The following table provides a summary of warrants outstanding, issued or exercised for the nine months ended September 30, 2015 . Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of September 30, 2015 . Series June 2013 and July 2013 March 2015 Series B Warrants December 2013 2013 Convertible Notes 2011 Totals Weighted Average Exercise Exercise Exercise Exercise Exercise Exercise Shares Price Shares Price Shares Price Shares Price Shares Price Shares Price Balance, December 31, 2014 - $ - $ $ $ $ $ Issuances - - - - - - - - Exercises - - - - - - - - Balance, September 30, 2015 $ $ $ $ $ $ Aggregate proceeds if exercised $ $ $ $ $ $

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity (Deficit) [Abstract]
Stockholders' Equity (Deficit)	7. Stockholders’ Equity (Deficit) On March 16, 2015, the Company issued and sold 1,575,758 shares of common stock in a private placement at a price of $ 8.25 per share, for aggregate proceeds of $ 13.0 million. In conjunction with this private placement, the Company issued warrants to purchase an aggregate of 393,948 shares of common stock at an exercise price of $ 10.75 per share to the purchasers of the common stock. The Company paid $ 833,000 in fees to its placement agents, along with the issuance of warrants to purchase an aggregate of 94,548 shares of common stock at an exercise price of $ 10.75 per share. The Company valued these warrants as liability instruments and recorded a liability of $ 4,210,000 as of March 16, 2015. In the first quarter of 2015, the Company recorded $ 213,000 of other expenses representing the portion of the initial warrant value of the placement agent warrants related to the initial fair value of the warrants issued to the purchasers of the common stock. The remainder of the initial fair value of the warrants of $ 3,998,000 was treated as a reduction of additional paid-in-capital. In addition, $ 218,000 of the fees paid to its placement agent were expensed as other expenses in the nine months ended September 30, 2015 as they also represented issuance costs related to the initial fair value of the warrants issued to the purchasers of the common stock.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2015
Stock-Based Compensation [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation The Company’s 2013 Stock Incentive Plan (Stock Incentive Plan) provides for the issuance of long-term incentive awards, or awards, in the form of non-qualified and incentive stock options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for stock o ptions must not be less than the fair market value of the underlying shares on the date of grant. Stock o ptions expire no later than ten years from the date of grant and generally vest and become exercisable over a four -year period following the date of grant. Every non-employee member of the Company’s Board of Directors may also receive an annual non-qualified stock o ption or restricted stock unit grant. Upon the exercise of stock o ptions, the Company issues the resulting shares from shares reserved for issuance under the Stock Incentive Plan. Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. The estimated grant-date fair value of the Company’s stock-based awards is amortized ratably over the awards’ service periods. Stock-based compensation expense recognized was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Research and development $ $ $ $ General and administrative Severance charge Total stock-based compensation $ $ $ $ The following table summarizes stock option activity for the nine months ended September 30, 2015 : Options Outstanding Average Weighted Remaining Shares Average Contractual Available Exercise Term Intrinsic For Grant Shares Price (Years) Value Balance, December 31, 2014 $ $ Increase in authorized shares Granted - - Exercised - - Forfeited - - Expired - - - Balance, September 30, 2015 $ $ Vested or expected to vest at September 30, 2015 $ $ - Exercisable at September 30, 2015 $ $ - The intrinsic value of options exercisable as of September 30, 2015 was $ 0.0 million, based on the Company’s closing stock price of $ 3.95 per share and a weighted average exercise price of $ 11.45 per share. The Company uses the Black-Scholes option-pricing model to estimate the fair value of standard stock options at the grant date. The Black-Scholes model requires the Company to make certain estimates and assumptions, including estimating the fair value of the Company’s common stock, assumptions related to the expected price volatility of the Company’s common stock, the period during which the options will be outstanding, the rate of return on risk-free investments and the expected dividend yield for the Company’s common stock. The Company uses Monte Carlo valuation models to estimate the fair value of certain stock options with market-based vesting requirements. This method of option pricing involves the use of inputs such as the market value of the Company’s common stock, stock price volatility, the period during which the options will be outstanding, the rate of return on risk-free investments, expected dividend yield for the Company’s stock, and certain estimates of future value of the Company’s common stock. During the third quarter of 2015, the Company issued 547,181 common stock options to its executives and board members with an average exercise price $ 8.72 per share. Included in this amount were 399,716 stock options, with an exercise price of $ 9.45 , to its Chief Executive Officer, pursuant to his employment agreement dated April 24, 2015. As of September 30, 2015 , there was $ 4.4 million of total unrecognized compensation expense related to unvested stock options that will be recognized over the weighted average remaining period of 1.98 years. Shares Reserved For Further Issuance As of September 30, 2015 , the Company had reserved shares of its common stock for future issuance as follows: Shares Reserved Stock options outstanding Available for future grants under the Stock Incentive Plan Warrants Total shares reserved

Collaborative and Other Agreeme

Collaborative and Other Agreements	9 Months Ended
	Sep. 30, 2015
Collaborative and Other Agreements [Abstract]
Collaborative and Other Agreements	9. Collaborative and Other Agreements In June 2013, the Company entered into a Collaborative Research and Development Agreement with the United States Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research. The Collaborative Research and Development Agreement is focused on developing and commercializing bacteriophage therapeutics to treat S. aureus infections. During the three and nine months ended September 30, 2015 , the Company recorded no payments under the Collaborative Research and Development Agreement. During the three and nine months ended September 30, 2014 , the Company paid Walter Reed Army Institute of Research $ 0 and $ 202,000 , respectively, for services provided under the Collaborative Research and Development Agreement. In March 2013, the Company entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation. This agreement allows the Company to utilize Intrexon’s synthetic biology platform for the identification, development and production of bacteriophage-containing human therapeutics. The Company paid a one-time technology access fee in 2013 to Intrexon of $ 3,000,000 in common stock. Pursuant to the agreement, the Company is required to pay Intrexon, in cash or stock, milestone fees of $ 2,500,000 for the initiation and commencement of the first Phase 2 trial and $ 5,000,000 upon the first regulatory approval of any product in any major market country. With regard to each product sold by the Company, the Company is required to pay, in cash, tiered royalties on a quarterly basis based on net sales of AmpliPhi Products, calculated on a product-by-product basis. No milestones have been met and no milestone payments have been paid to Intrexon through September 30, 2015 . During the three and nine months ended September 30, 2015 , the Company recorded $ 37,000 and $ 81,000 , respectively , in expenses under the Exclusive Channel Collaboration Agreement, with cash payments totaling $ 40,000 and $ 75,000 , respectively. During the three and nine months ended September 30, 2014 , the Company recorded $ 304,000 and $ 843,000 , respectively, in expenses under the Exclusive Channel Collaboration Agreement, with cash payments totaling $ 214,000 and $ 730,000 , respectively. In April 2013, the Company entered into a collaboration agreement with the University of Leicester to develop a phage therapy that targets and kills all toxin types of C. difficle. In August 2013, the Company entered into a collaboration agreement with both the University of Leicester and the University of Glasgow to carry out certain animal model development work. Under these agreements, which are referred to collectively as the Leicester Development Agreements, the Company provides payments to the University of Leicester to carry out in vitro and to the University of Glasgow to carry out animal model development work on the University of Leicester’s development of a bacteriophage therapeutic to resolve C. difficile infections. The Company licensed related patents, materials and know-how from the University of Leicester. Under the Leicester Development Agreements, the University of Leicester will provide the bacteriophage and act as overall project coordinator for the development work. All rights, title and interest to any intellectual property developed under the Leicester Development Agreements belong to the Company. Under the Leicester License Agreement, the Company has exclusive rights to certain background intellectual property of the University of Leicester, for which it will pay the University of Leicester royalties based on product sales and make certain milestone payments based on product development. In October 2014, the Company renewed this collaboration, effective as of November 9, 2014. This agreement expired November 12, 2015 . The Company expects the agreement to be renewed. During the three and nine months ended September 30, 2015 , the Company paid and expensed amounts to the University of Leicester under the Leicester Development Agreements in the amount of $ 55,000 and $ 220,000 , respectively. During t he three and nine months ended September 30, 2014 , the Company paid and expensed amounts to the University of Leicester under the Leicester Development Agreements in the amount of $ 0 and $ 166,000 , respectively . The Company paid and expenses amounts to the University of Glasgow under the Leicester Development Agreements of $ 0 and $ 61,000 for the three and nine months ended September 30, 2015 respectively. The Company paid and expensed amounts to the University of Glasgow under the Leicester Development Agreements of $ 61,000 and $ 184,000 for the three and nine months ended September 30, 2014 , respectively. In September 2015, the Company entered into a non-exclusive patent license agreement with Takara Bio Inc. (the Takara Agreement). Under this agreement Takara licensed certain patents related to AAV1 Vector gene delivery systems, for which the Company is an exclusive licensor with the University of Pennsylvania. The Company received a $ 40,000 non-refundable, up-front licensing payment and shall receive royalties from Takara of 12.0 % of net license product sales and 6.0 % of service revenues associated with the licensed products. The agreement calls for minimum annual royalties of $ 15,000 commencing on February 28, 2016. In addition, the Takara Agreement provides milestone fees to the Company of $ 30,000 of the first $ 1,000,000 of licensed product revenues by Takara and an additional $ 40,000 when cumulative net sales of the licensed product by Takara exceed $ 2,000,000 .

Severance Charge

Severance Charge	9 Months Ended
	Sep. 30, 2015
Severance Charge [Abstract]
Severance Charge	10. Severance Charge On September 15, 2014, by mutual agreement of the Board of Directors (the “Board”) of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company, effective September 15, 2014. In accordance with Mr. Young’s employment agreements, the Company recorded a severance charge in 2014 of $ 1,864,000 related to severance-period compensation and benefits and stock-based compensation expense related to the accelerated vesting of stock options. In the third quarter of 2015, the Company recorded an additional severance charge of $ 289,000 related to the departure of an executive, which included severance period compensation and benefits and stock-based compensation related to the accelerated vesting of stock options. The severance accrual as of December 31, 2014 and September 30, 2015 is as follows: Accrued severance, December 31, 2014 $ Cash payments in 2015 Additions in 2015 Accrued severance, September 30, 2015 $

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2015
Legal Proceedings [Abstract]
Legal Proceedings	11. Legal Proceedings The Company is not involved in any legal proceedings that it expects to have a material adverse effect on its business, financial condition, results of operations and cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On November 2, 2015 , the Company signed a Clinical Trial Agreement with the Adelaide Research & Innovation P ty L td on behalf of the University of Adelaide for the conduct of a Phase One Investigator Initiated clinical trial to evaluate the safety and tolerability of AB-SA01 in patients with chronic rhinosinusitis associated with Staphylococcus aureus infection. The study will be co nducted at the Queen Elizabeth H ospital Department of Otolaryngology Head and Neck Surgery. On November 5, 2015, the Company’s Board of Directors appointed Vijay Samant as a Class II director of the Company and Paul C. Grint, M.D. as a Clas s III director of the Company. In connection with their appointments on November 5, 2015, each of Mr. Samant and Dr. Grint was granted, under the Company’s 2013 Stock Incentive Plan, a stock option to purchase 16,200 of the Company’s common stock at an exercise price per share of $ 5.65 , which was the closing price of the Company’s common stock on the NYSE MKT on the date of grant. Each of the stock options vests as follows: 25 % of the shares subject to the option will vest one year following the date of grant, and thereafter the remaining shares will vest in equal monthly installments over the following 36 months. As non-employee directors, each of Mr. Samant and Dr. Grint will also be entitled to receive an annual cash retainer of $ 40,000 for his service on the Board .

Significant Accounting Polici19

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10 ‑K, filed with the Securities and Exchange Commission (SEC). The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted account principles as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).
Unaudited Interim Financial Statements	In the opinion of management, the accompanying financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2015 and the results of its operations for the three and nine months ended September 30, 2015 and 2014 . Interim results are not necessarily indicative of results for the full year or any future period.
Use of Estimates	Use of Estimates Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: the determination of the fair value of stock-based awards, the fair value of liability-classified preferred stock derivatives, the fair value of liability-classified warrants, the valuation of long-lived assets, including in-process research and development (IPR&D), patents and goodwill, accrued expenses and the recoverability of the Company's net deferred tax assets and related valuation allowance.
Reverse Stock Split Policy	Reverse Stock Split On August 3, 2015, the Company filed Articles of Amendment to Amended and Restated Articles of Incorporation with the Secretary of State of the State of Washington that effected a 1-for-50 (1: 50 ) reverse stock split of its common stock, par value $ 0.01 per share , effective August 7, 2015. On August 3, 2015, the Company increased its authorized common stock, from 445,000,000 to 670,000,000 shares. The par value of its common stock was unchanged at $0.01 per share, post-split. All warrant, stock option, and per share information in the consolidated financial statements gives retroactive effect to the 1-for-50 reverse stock split that was effected on August 7, 2015.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions. Cash equivalents include short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost plus accrued interest, which approximates fair market value.
Accounts Receivable	Accounts Receivable Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on an assessment of the probable collection from specific customer accounts and other known factors. As of September 30, 2015 and December 31, 2014 , management determined no allowance for doubtful accounts was required.
In Process Research & Development and Goodwill	In-Process Research & Development and Goodwill In-process research & development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. We review the carrying value of IPR&D and goodwill for potential impairment on an annual basis and at any time that events or business conditions indicate that it may be impaired. As permitted under Accounting Standards Codification Topic 350 (ASC 350), through December 31, 2014 , we have elected to base our assessment of potential impairment on qualitative factors. Based on our assessment, IPR&D and goodwill were not impaired as of December 31, 2014 .
Warrant and Preferred Shares Conversion Feature Liability	Warrant and Preferred Shares Conversion Feature Liability The Company accounts for warrant and preferred share features with anti-dilution adjustment provisions under the applicable accounting guidance which requires the warrant and the preferred share feature to be recorded as a liability and adjusted to fair value at each reporting period.
Foreign Currency Translations and Transactions	Foreign Currency Translations and Transactions The functional currency of our wholly-owned subsidiaries is the U.S. dollar.
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) The Company recorded no comprehensive income other than net income for the periods reported.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern , which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

Fair Value of Financial Asset20

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Derivatives And Fair Value [Line Items]
Financial Liabilities Measured at Fair Value	The following fair value hierarchy table presents information about each major category of the Company's financial liabilities measured at fair value on a recurring basis: Quoted Prices in Active Markets Significant Other Significant for Identical Observable Inputs Unobservable Items (Level 1) (Level 2) Inputs (Level 3) Total September 30, 2015 Liabilities Series B preferred stock derivative liability $ - $ - $ $ Warrant liability - - Total liabilities $ - $ - $ $ December 31, 2014 Liabilities Series B preferred stock derivative liability $ - $ - $ $ Warrant liability - - Total liabilities $ - $ - $ $
Changes in Fair Value of Derivative and Warrant Liability	The following table sets forth a summary of changes in the fair value of the Company's Series B redeemable convertible preferred stock derivative and warrant liability, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy, wherein fair value is estimated using significant unobservable inputs: Series B Preferred Warrant Stock Derivative Liability Liability Balance, December 31, 2014 $ $ Issuances - Exercises - Conversions to common stock - Warrants reclassified from liabilities to equity due to amendment of warrants - Warrants reclassified from liabilities to equity due to increase in authorized shares - Changes in estimated fair value Balance, September 30, 2015 $ $
Series B redeemable convertible preferred stock [Member]
Derivatives And Fair Value [Line Items]
Valuation Assumptions Used	The following assumptions were used at September 30, 2015 and December 31, 2014 : September 30, December 31, 2015 2014 Volatility % % Expected term (years) Risk-free interest rate % % Common stock dividend yield % % Minimum non-diluting issuance price $ $ Common stock closing price $ $
Warrant Liability [Member]
Derivatives And Fair Value [Line Items]
Valuation Assumptions Used	The following assumptions were used at September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 Series (1) Series (1) June July December 2011 2011 2013 2013 2013 Volatility % % % % % Expected term (years) Risk-free interest rate % % % % % Dividend yield % % % % % Exercise price $ $ $ $ $ Common stock closing price $ $ $ $ $

Net (Loss) Income per Common 21

Net (Loss) Income per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Net (Loss) Income per Common Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the computation of basic and diluted net (loss) income per share for the periods indicated: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Basic and diluted net (loss) income per common share calculation: Net income $ $ $ $ Accretion of Series B redeemable convertible preferred stock Net (loss) income attributable to common stockholders $ $ $ $ Weighted average common shares outstanding - basic Net income (loss) per share of common stock - basic $ $ $ $ Weighted average common shares outstanding - diluted Net income (loss) per share of common stock - diluted $ $ $ $
Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding	The following outstanding securities at September 30, 2015 and 2014 have been excluded from the computation of diluted weighted shares outstanding for the nine months ended September 30, 2015 and 2014 , as they would have been anti-dilutive: September 30, September 30, 2015 2014 Options Warrants - Series B redeemable convertible preferred stock as converted - Escrow - Total

Redeemable Convertible Prefer22

Redeemable Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2015
Redeemable Convertible Preferred Stock
Schedule of Conversions of Series B Preferred to Common Stock	The following table summarizes the conversions of Series B shares to common stock pursuant to Series B shareholder elections during the nine months ended September 30, 2015 : Amount Reclassified Series B Common from Liability Conversion Shares Stock into Stockholders' Date Converted Issued Equity (1) April 8, 2015 $ May 4, 2015 May 11, 2015 July 16, 2015 August 13, 2015 Totals $

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2015
Warrants [Abstract]
Summary of Warrant Information	The following table provides a summary of warrants outstanding, issued or exercised for the nine months ended September 30, 2015 . Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of September 30, 2015 . Series June 2013 and July 2013 March 2015 Series B Warrants December 2013 2013 Convertible Notes 2011 Totals Weighted Average Exercise Exercise Exercise Exercise Exercise Exercise Shares Price Shares Price Shares Price Shares Price Shares Price Shares Price Balance, December 31, 2014 - $ - $ $ $ $ $ Issuances - - - - - - - - Exercises - - - - - - - - Balance, September 30, 2015 $ $ $ $ $ $ Aggregate proceeds if exercised $ $ $ $ $ $

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Stock-Based Compensation [Abstract]
Allocation of Stock-Based Compensation Expenses	The estimated grant-date fair value of the Company’s stock-based awards is amortized ratably over the awards’ service periods. Stock-based compensation expense recognized was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Research and development $ $ $ $ General and administrative Severance charge Total stock-based compensation $ $ $ $
Summary of Stock Option Activity	The following table summarizes stock option activity for the nine months ended September 30, 2015 : Options Outstanding Average Weighted Remaining Shares Average Contractual Available Exercise Term Intrinsic For Grant Shares Price (Years) Value Balance, December 31, 2014 $ $ Increase in authorized shares Granted - - Exercised - - Forfeited - - Expired - - - Balance, September 30, 2015 $ $ Vested or expected to vest at September 30, 2015 $ $ - Exercisable at September 30, 2015 $ $ -
Shares Reserved for Future Issuance	As of September 30, 2015 , the Company had reserved shares of its common stock for future issuance as follows: Shares Reserved Stock options outstanding Available for future grants under the Stock Incentive Plan Warrants Total shares reserved

Severance Charge (Tables)

Severance Charge (Tables)	9 Months Ended
	Sep. 30, 2015
Severance Charge [Abstract]
Severance Charges	In the third quarter of 2015, the Company recorded an additional severance charge of $ 289,000 related to the departure of an executive, which included severance period compensation and benefits and stock-based compensation related to the accelerated vesting of stock options. The severance accrual as of December 31, 2014 and September 30, 2015 is as follows: Accrued severance, December 31, 2014 $ Cash payments in 2015 Additions in 2015 Accrued severance, September 30, 2015 $

Organization and Description 26

Organization and Description of the Business (Details) - USD ($)	Mar. 16, 2015	Mar. 31, 2015	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Retained earnings (accumulated deficit)				$ (360,291,000)	$ (362,006,000)
Proceeds from issuance of private placement, gross			$ 13,000,000
Proceeds from issuance of private placement, net of offering costs				$ 12,384,000
Private Placement [Member]
Proceeds from issuance of private placement, gross	$ 13,000,000
Proceeds from issuance of private placement, net of offering costs		$ 12,400,000

Significant Accounting Polici27

Significant Accounting Policies (Details)	Aug. 03, 2015$ / sharesshares	Sep. 30, 2015$ / sharesshares	Aug. 02, 2015shares	Dec. 31, 2014$ / sharesshares
Significant Accounting Policies [Abstract]
Reverse stock split, description	1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share
Conversion ratio of reverse stock split	50
Common stock, shares authorized | shares	670,000,000	670,000,000	445,000,000	445,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01		$ 0.01

Fair Value of Financial Asset28

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability	$ 2,127,000	$ 12,320,000
Warrant liability	10,000	5,826,000
Total liabilities	$ 2,137,000	$ 18,146,000
Fair Value, Inputs, Level 1 [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability
Warrant liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability
Warrant liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability	$ 2,127,000	$ 12,320,000
Warrant liability	10,000	5,826,000
Total liabilities	$ 2,137,000	$ 18,146,000

Fair Value of Financial Asset29

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Change in Fair Value of Series B Convertible Stock) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Derivatives And Fair Value [Line Items]
Balance, Warrant Liability	$ 5,826,000
Balance, Series B Redeemable Preferred Stock	12,320,000
Balance, Warrant Liability	10,000
Balance, Series B Redeemable Preferred Stock	2,127,000
Series B redeemable convertible preferred stock [Member]
Derivatives And Fair Value [Line Items]
Balance, Series B Redeemable Preferred Stock	12,320,000
Conversions to common stock	(1,496,000)
Changes in estimated fair value	(8,697,000)
Balance, Series B Redeemable Preferred Stock	2,127,000
Warrant Liability [Member]
Derivatives And Fair Value [Line Items]
Balance, Warrant Liability	5,826,000
Issuance	4,210,000
Exercises	(676,000)
Warrants reclassified from liabilities to equity due to amendment of warrants	(5,462,000)
Warrants reclassified from liabilities to equity due to increase in authorized shares	(3,281,000)
Changes in estimated fair value	(607,000)
Balance, Warrant Liability	$ 10,000

Fair Value of Financial Asset30

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Valuation Assumptions for Warrants) (Details) - $ / shares		9 Months Ended	12 Months Ended
		Sep. 30, 2015	Dec. 31, 2014
2011 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]	112.00%	155.00%
Expected term (years)	[1]	1 year 2 months 23 days	1 year 11 months 23 days
Risk-free interest rate	[1]	0.40%	0.67%
Dividend yield	[1]	0.00%	0.00%
Exercise price	[1]	$ 23	$ 23
Common stock closing price	[1]	$ 3.95	$ 10.50
June 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		155.00%
Expected term (years)	[1]		3 years 5 months 27 days
Risk-free interest rate	[1]		1.23%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 7
Common stock closing price	[1]		$ 10.50
July 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		155.00%
Expected term (years)	[1]		3 years 6 months 15 days
Risk-free interest rate	[1]		1.25%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 7
Common stock closing price	[1]		$ 10.50
December 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		151.00%
Expected term (years)	[1]		3 years 11 months 23 days
Risk-free interest rate	[1]		1.37%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 12.50
Common stock closing price	[1]		$ 10.50
[1]	See Note 6 - Warrants below for further description of the respective series of warrants.

Fair Value of Financial Asset31

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Valuation Assumptions Used for Series B Convertible Stock) (Details) - Series B redeemable convertible preferred stock [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Volatility	102.00%	91.00%
Expected term (years)	1 year 7 months 17 days	1 year 4 months
Risk-free interest rate	0.08%	0.36%
Dividend yield	0.00%	0.00%
Exercise price	$ 7	$ 7
Common stock closing price	$ 3.95	$ 10.50

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share (Basic and Diluted Income (Loss) Per Share) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Basic and diluted net income (loss) per common share calculation:
Net income	$ 5,439,000	$ 21,207,000	$ 1,715,000	$ 23,773,000	$ 23,109,000
Accretion of redeemable convertible preferred stock	(7,163,000)	(323,000)	(9,329,000)	(955,000)
Net (loss) income attributable to common stockholders	$ (1,724,000)	$ 20,884,000	$ (7,614,000)	$ 22,818,000
Weighted average number of shares of common stock outstanding - basic	5,813,063	3,743,182	5,247,508	3,688,903
Net (loss) income per share of common stock - basic	$ (0.30)	$ 5.58	$ (1.45)	$ 6.19
Weighted average number of shares of common stock outstanding - diluted	5,813,063	6,319,802	5,247,508	6,472,093
Net (loss) income per share of common stock - diluted	$ (0.30)	$ 3.30	$ (1.45)	$ 3.53

Net Income (Loss) per Common 33

Net Income (Loss) per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	3,346,378	255,280
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	631,126	15,280
Warrant Liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,209,681
Series B redeemable convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,505,571
Escrow [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		240,000

Redeemable Convertible Prefer34

Redeemable Convertible Preferred Stock (Details)		Aug. 13, 2015USD ($)shares	Aug. 03, 2015	Jul. 16, 2015USD ($)shares	May. 11, 2015USD ($)shares	May. 04, 2015USD ($)shares	Apr. 08, 2015USD ($)shares	Jun. 13, 2013USD ($)$ / sharesshares	Jun. 13, 2013$ / sharesshares	Sep. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)$ / sharesshares
Class of Stock [Line Items]
Preferred Stock dividend rate												10.00%
Trigger price per share for redemption and conversion features of embedded derivative | $ / shares												$ 7
Number of shares converted | shares		500,000		262,500	250,000	23,587	107,100					1,143,187
Shares of common stock issued upon conversion of preferred stock | shares		100,000		52,500	50,000	4,717	21,420					228,637
Amount reclassified from Series B derivative liability into shareholders' equity	[1]	$ 542,000		$ 318,000	$ 381,000	$ 36,000	$ 219,000			$ 1,496,000		$ 1,496,000
Gain (loss) on remeasurement of conversion feature												8,697,000
Fair value of Series B stock conversion liability										2,127,000		2,127,000
Amount reclassified to Series B redeemable convertible stock												(8,337,000)
Reverse stock split, description			1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share
Conversion ratio of reverse stock split			50
Dividends payable										$ 368,000		$ 368,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares								9,357,935	9,357,935
Preferred Stock, initial stated value per share | $ / shares								$ 1.40	$ 1.40
Preferred Stock, par value per share | $ / shares								$ 0.01	$ 0.01
Number of shares of common stock for which each Series B share can be converted									0.20
Minimum proceeds from conversion of stock upon closing of offering								$ 7,000,000
Preferred Stock, liquidation preference per share | $ / shares										$ 1.40		$ 1.40
Gain (loss) on remeasurement of conversion feature										$ 7,045,000
Amount reclassified to Series B redeemable convertible stock											$ 1,492,000	$ 8,337,000
Increase in amount reclassified to Series B Preferred stock										$ 6,845,000
[1]	Not inclusive of liabilities for dividends payable upon conversion of these shares.

Redeemable Convertible Prefer35

Redeemable Convertible Preferred Stock (Schedule of Conversions of Series B to Common Stock) (Details) - USD ($)		Aug. 13, 2015	Jul. 16, 2015	May. 11, 2015	May. 04, 2015	Apr. 08, 2015	Sep. 30, 2015
Redeemable Convertible Preferred Stock
Number of shares converted		500,000	262,500	250,000	23,587	107,100	1,143,187
Shares of common stock issued upon conversion of preferred stock		100,000	52,500	50,000	4,717	21,420	228,637
Amount reclassified from Series B derivative liability into shareholders' equity	[1]	$ 542,000	$ 318,000	$ 381,000	$ 36,000	$ 219,000	$ 1,496,000
[1]	Not inclusive of liabilities for dividends payable upon conversion of these shares.

Warrants (Narrative) (Details)

Warrants (Narrative) (Details)

Aug. 13, 2015shares

Aug. 03, 2015USD ($)shares

Jul. 16, 2015shares

May. 11, 2015shares

May. 04, 2015shares

Apr. 29, 2015USD ($)shares

Apr. 08, 2015shares

Apr. 01, 2015USD ($)shares

Mar. 16, 2015USD ($)$ / sharesshares

Dec. 22, 2011$ / sharesshares

Jul. 15, 2013USD ($)$ / sharesshares

Sep. 30, 2015USD ($)$ / sharesshares

Mar. 31, 2015USD ($)

Sep. 30, 2014USD ($)

May. 31, 2013$ / sharesshares

Sep. 30, 2015USD ($)$ / sharesshares

Sep. 30, 2014USD ($)

Aug. 02, 2015shares

May. 08, 2015USD ($)

Dec. 31, 2014USD ($)shares

Dec. 31, 2013$ / sharesshares

Class of Warrant or Right [Line Items]

Shares issued in transaction | shares

1,440,140

Sale of stock, price per share | $ / shares

$ 3.95

$ 3.95

$ 12.50

Number of securities called by warrants | shares

393,939

Exercise price of warrants | $ / shares

$ 10.75

Warrant liquidation charges if warrants not exercised according to terms

$ 2,500,000

Warrant liability

$ 10,000

10,000

$ 5,826,000

Other expenses related to issuance of warrants

$ 213,000

$ 213,000

Shares issued upon exercise of warrants | shares

100,000

52,500

50,000

4,717

21,420

228,637

Amount reclassified from warrant liability into equity

$ 3,281,000

$ 46,000

$ 630,000

Reverse stock split, description

1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share

Conversion ratio of reverse stock split

50

Common stock, shares authorized | shares

670,000,000

670,000,000

670,000,000

445,000,000

445,000,000

Fair value of liquidated damages reclassified to shareholders' equity

$ 120,000

Gain (loss) on remeasurement of fair value of warrant liability

$ 693,000

$ 7,079,000

$ 607,000

$ 9,245,000

Series B Placement - June 26, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 4,285,000

Shares issued upon exercise of warrants | shares

4,524

52,120

Series B Placement - July 15, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 674,000

Investors [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 3,396,000

Placement Agent [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

94,548

86,408

Exercise price of warrants | $ / shares

$ 10.750

$ 12.50

Warrant liability

$ 814,000

Other expenses related to issuance of warrants

$ 218,000

Down Round Position [Member]

Class of Warrant or Right [Line Items]

Exercise price of warrants | $ / shares

$ 8.250

Amount reclassified from warrant liability into equity

$ 5,462,000

Biocontrol Business Combination [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

27,103

Exercise price of warrants | $ / shares

$ 23

Warrant expiration date

December 2,016

Convertible Notes Payable [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

140,608

Exercise price of warrants | $ / shares

$ 7

Warrant expiration date

February through May 2018

Private Placement [Member]

Class of Warrant or Right [Line Items]

Sale of stock, number of shares issued in transaction | shares

1,575,758

Shares issued in transaction | shares

1,575,758

Sale of stock, price per share | $ / shares

$ 8.250

Number of securities called by warrants | shares

393,948

Exercise price of warrants | $ / shares

$ 10.750

Warrant liability

$ 4,210,000

Warrant expiration date

March 2,020

Private Placement - Series B Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

600,804

Exercise price of warrants | $ / shares

$ 7

Private Placement - Series B Preferred Stock [Member] | Series B Placement - June 26, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant expiration date

June 2,018

Private Placement - Series B Preferred Stock [Member] | Series B Placement - July 15, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant expiration date

July 2,018

Private Placement - Series B Preferred Stock [Member] | Placement Agent [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 759,000

Warrants (Number of Warrants, E

Warrants (Number of Warrants, Exercise Price, Aggregate Proceeds of Warrants if Exercised) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issuances	4,210,000
Shares, Balance at September 30, 2015	1,209,681
Warrants Through March 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014
Shares, Issuances	488,496
Shares, Balance at September 30, 2015	488,496
Aggregate proceeds if exercised | $	$ 5,251,332
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares
Weighted Average Exercise Price, Issuances | $ / shares	$ 10.75
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 10.75
2013 Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	523,705
Shares, Exercises	(56,645)
Shares, Balance at September 30, 2015	467,060
Aggregate proceeds if exercised | $	$ 3,269,420
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 7
Weighted Average Exercise Price, Exercises | $ / shares	7
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 7
Warrants Through December 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	86,410
Shares, Balance at September 30, 2015	86,410
Aggregate proceeds if exercised | $	$ 1,080,125
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 12.50
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 12.50
Convertible Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	140,611
Shares, Balance at September 30, 2015	140,611
Aggregate proceeds if exercised | $	$ 984,277
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 7
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 7
Warrants Through 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	27,104
Shares, Balance at September 30, 2015	27,104
Aggregate proceeds if exercised | $	$ 623,392
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 23
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 23
Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	777,830
Shares, Issuances	488,496
Shares, Exercises	(56,645)
Shares, Balance at September 30, 2015	1,209,681
Aggregate proceeds if exercised | $	$ 11,975,842
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 8
Weighted Average Exercise Price, Issuances | $ / shares	10.75
Weighted Average Exercise Price, Exercises | $ / shares	7
Weighted Average Exercise Price, Outstanding at September 30, 2015 | $ / shares	$ 9.90

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details) - USD ($)	Mar. 16, 2015	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Sale of stock, price per share			$ 3.95		$ 12.50
Proceeds from issuance of private placement, gross		$ 13,000,000
Number of securities called by warrants	393,939
Exercise price of warrants	$ 10.75
Warrant liability			$ 10,000	$ 5,826,000
Decrease to additional paid-in capital resulting from warrants issued		(3,998,000)
Other expenses related to issuance of warrants		$ 213,000	213,000
Placement Agent [Member]
Class of Stock [Line Items]
Number of securities called by warrants	94,548				86,408
Exercise price of warrants	$ 10.750				$ 12.50
Fees paid to placement agent	$ 833,000
Warrant liability	$ 814,000
Other expenses related to issuance of warrants			$ 218,000
Private Placement [Member]
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction	1,575,758
Sale of stock, price per share	$ 8.250
Proceeds from issuance of private placement, gross	$ 13,000,000
Number of securities called by warrants	393,948
Exercise price of warrants	$ 10.750
Warrant liability	$ 4,210,000

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2013
Vesting period of share-based compensation award		4 years
Expiration period of share-based payment award		10 years
Unrecognized compensation cost related to unvested options	$ 4.4	$ 4.4
Weighted-average remaining period for recognition of compensation costs related to unvested options	1 year 11 months 23 days
Weighted average exercise price of options outstanding	$ 11.45	$ 11.45
Closing stock price	3.95	$ 3.95	$ 12.50
Options granted in stock option grant		547,181
Exercise price of options granted	$ 8.72	$ 8.72
Board Members and Executives [Member]
Options granted in stock option grant	547,181
Chief Executive Officer [Member]
Options granted in stock option grant	399,716
Exercise price of options granted	$ 9.45

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 149,000	$ 1,408,000	$ 253,000	$ 1,875,000
Employee Severance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	4,000	1,161,000	4,000	1,161,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	29,000	38,000	88,000	116,000
General and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 116,000	$ 209,000	$ 161,000	$ 598,000

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Stock-Based Compensation [Abstract]
Shares Available for Grant, Balance at December 31, 2014		785,000
Shares Available for Grant, Increase in authorized shares		520,000
Shares Available for Grant, Granted		(547,181)
Shares Available for Grant, Exercised
Shares Available for Grant, Forfeited		4,812
Shares Available for Grant, Expired
Shares Available for Grant, Balance at September 30, 2015	762,631	762,631	785,000
Shares, Balance at December 31, 2014		440,695
Shares, Granted		547,181
Shares, Exercises		(214,815)
Shares, Forfeited		(4,812)
Shares, Expired		(137,123)
Shares, Balance at September 30, 2015	631,126	631,126	440,695
Shares, Vested or expected to vest at September 30, 2015	499,995	499,995
Shares, Exercisable at September 30, 2015	66,205	66,205
Weighted Average Exercise Price, Outstanding at December 31, 2014		$ 9.37
Weighted Average Exercise Price, Granted	$ 8.72	8.72
Weighted Average Exercise Price, Exercised		8
Weighted Average Exercise Price, Forfeited		13.64
Weighted Average Exercise Price, Expired		10.19
Weighted Average Exercise Price, Outstanding at September 30, 2015	9.06	9.06	$ 9.37
Weighted Average Exercise Price, Vested or expected to vest at September 30, 2015	9.05	9.05
Weighted Average Exercise Price, Exercisable at September 30, 2015	$ 11.45	$ 11.45
Average Remaining Contractual Term (Years), Outstanding at December 31, 2014		9 years 4 months 17 days	8 years 2 months 5 days
Average Remaining Contractual Term (Years), Outstanding at September 30, 2015		9 years 4 months 17 days	8 years 2 months 5 days
Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2015		9 years 3 months 4 days
Average Remaining Contractual Term (Years), Exercisable at September 30, 2015		5 years 11 months 23 days
Intrinsic Value, Outstanding at December 31, 2014		$ 640,837
Intrinsic Value, Exercised		(383,994)
Intrinsic Value, Outstanding at September 30, 2015	$ 256,843	$ 256,843	$ 640,837

Stock-Based Compensation (Share

Stock-Based Compensation (Shares Reserved for Future Issuance) (Details) - shares	Sep. 30, 2015	Dec. 31, 2014
Stock-Based Compensation [Abstract]
Stock options outstanding	631,126	440,695
Available for future grants under the Stock Incentive Plan	762,631	785,000
Warrants	1,209,681
Total shares reserved	2,603,438

Collaborative and Other Agree43

Collaborative and Other Agreements (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fees Payable Upon Commencement Of The First Phase 2 Trial	$ 2,500,000		$ 2,500,000
Licensing Payments Received	143,000	$ 103,000	347,000	$ 308,000
Intrexon Corporation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fees Payable Upon First Regulatory Approval	5,000,000		5,000,000
Expenses Incurred Under Channel Collaborative Agreement	37,000	304,000	81,000	843,000
Cash Paid For Channel Collaboration Agreement	40,000	214,000	75,000	730,000
University Of Leicester [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments For Services Under Collaborative Agreement	$ 55,000	0	220,000	166,000
Collaborative Agreement Expiration Date	Nov. 12, 2015
University Of Glasgow [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments For Services Under Collaborative Agreement	$ 0	61,000	61,000	184,000
Walter Reed Army Institute Of Research [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments For Services Under Collaborative Agreement	0	$ 0	$ 0	$ 202,000
Takara Bio Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Licensing Payments Received	$ 40,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of License Product Sales Receivable	12.00%
Percent of License Product Service Revenues Receivable	6.00%
Minimum Annual Royalty Payments Receivable	$ 15,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member] | Criteria One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent Licensing Receivable	30,000
Licensed Product Revenues Milestone Benchmark	1,000,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member] | Criteria Two [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent Licensing Receivable	40,000
Licensed Product Net Sales Milestone Benchmark	$ 2,000,000
Common Stock [Member] | Intrexon Corporation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Stock Issued During Period, Value, Issued for Services					$ 3,000,000

Severance Charge (Narrative) (D

Severance Charge (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Severance Charge [Abstract]
Severance Costs	$ 289,000	$ 1,840,000	$ 289,000	$ 1,840,000	$ 1,864,000

Severance Charge (Severance Acc

Severance Charge (Severance Accrual) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Severance Charge [Abstract]
Accrued severance, December 31, 2014	$ 555,000
Payments in 2015	(351,000)
Additions in 2015	287,000
Accrued severance, September 30, 2015	$ 491,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Nov. 05, 2015	Sep. 30, 2015	Sep. 30, 2015
Options granted in stock option grant			547,181
Exercise price of options granted		$ 8.72	$ 8.72
Vesting period of options granted			4 years
Subsequent Event [Member]
Vesting description of options granted	25% of the shares subject to the option will vest one year following the date of grant, and thereafter the remaining shares will vest in equal monthly installments over the following 36 months.
Subsequent Event [Member] | Class II Director [Member]
Options granted in stock option grant	16,200
Exercise price of options granted	$ 5.65
Annual retainer for non-employee director	$ 40,000
Subsequent Event [Member] | Class III Director [Member]
Options granted in stock option grant	16,200
Exercise price of options granted	$ 5.65
Annual retainer for non-employee director	$ 40,000
Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]
Percent of shares vesting	25.00%
Vesting period of options granted	1 year
Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting description of options granted	remaining shares will vest in equal monthly installments
Vesting period of options granted	36 months